Francisco Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Francisco Gonzalez has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
- Maria Alvarez Bermudez
Department of Biology, Faculty of Science, University of A Coruña, A Coruña, Spain
25 shared publications Rogelio Perez
18 shared publications- Maria del Carmen Romero
Department of Physiology, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
11 shared publications - Ana F. Vicente
Department of Physiology, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
9 shared publications - Jose Manuel Abalo-Lojo
Service of Ophthalmology, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
9 shared publications - Miguel López
Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain
7 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (20) , 5779-5806
POMC AMPKα1 deletion drives male-specific BAT thermogenesis and obesity resistance
Proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus (ARC) play a critical role in energy homeostasis. 5’-adenosine monophosphate-activated protein kinase (AMPK) is a serine/threonine kinase, which acts as the main energy sensor in the cell. The heterotrimeric AMPK results from the combination of a catalytic α subunit (α1, α2) with two regulatory subunits, β (β1, β2) and γ (γ1, γ2 and γ3). Hypothalamic AMPK plays a key role in the control of energy balance, but current evidence shows that the precise combination of its heterotrimeric components determines its physiological action. Our findings show that AMPKα1 ablation in POMC neurons has a sex-dependent protective effect against diet-induced obesity because of increased thermogenesis in brown adipose tissue (BAT) in males, but not in females. At the molecular level, deletion of AMPKα1 in POMC neurons disrupts the ARC phosphoproteome and is associated with ameliorated endoplasmic reticulum (ER) stress and reduced ceramide content. These findings highlight the complex function of the different AMPK subunits in the hypothalamic regulation of energy balance.
- 1 September 2026
- Published by Springer Nature in EMBO Reports
- Vol. 27 (20) , 5779-5806
Open AccessPOMC AMPKα1 deletion drives male-specific BAT thermogenesis and obesity resistance
Proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus (ARC) play a critical role in energy homeostasis. 5’-adenosine monophosphate-activated protein kinase (AMPK) is a serine/threonine kinase, which acts as the main energy sensor in the cell. The heterotrimeric AMPK results from the combination of a catalytic α subunit (α1, α2) with two regulatory subunits, β (β1, β2) and γ (γ1, γ2 and γ3). Hypothalamic AMPK plays a key role in the control of energy balance, but current evidence shows that the precise combination of its heterotrimeric components determines its physiological action. Our findings show that AMPKα1 ablation in POMC neurons has a sex-dependent protective effect against diet-induced obesity because of increased thermogenesis in brown adipose tissue (BAT) in males, but not in females. At the molecular level, deletion of AMPKα1 in POMC neurons disrupts the ARC phosphoproteome and is associated with ameliorated endoplasmic reticulum (ER) stress and reduced ceramide content. These findings highlight the complex function of the different AMPK subunits in the hypothalamic regulation of energy balance.
- Open Access
- 4 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6072
Fifteen-Year Longitudinal Changes in Peripapillary Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Background/Objectives: To evaluate changes in peripapillary retinal nerve fiber layer (pRNFL) thickness in patients with multiple sclerosis (MS) and healthy controls over a 15-year period. Methods: This is a retrospective, observational, longitudinal, case-control study. The study included 53 patients with relapsing-remitting MS and 44 age-matched healthy controls. pRNFL thickness was measured using optical coherence tomography (OCT) at baseline (2010) and 15 years later (2025) across 12 peripapillary sectors. Eyes were categorized into three groups: healthy control eyes (Control), eyes from MS patients without a history of optic neuritis (MSnoON), and eyes from MS patients with a history of optic neuritis (MS+ON). Median and interquartile range (IQR) were used for descriptive statistics. Non-parametric tests were applied for statistical analysis. Results: At baseline, the median pRNFL thickness was 94.8 µm in Control eyes, 86.3 µm in MSnoON eyes, and 69.5 µm in MS+ON eyes. After 15 years, the values were 88.5 µm, 80.8 µm, and 59.5 µm, respectively. Intragroup comparisons between 2010 and 2025 showed statistically significant reductions in pRNFL thickness across all three groups (Wilcoxon test, p < 0.05). Intergroup comparisons revealed significant differences among the three groups at both time points (Mann–Whitney test, p < 0.05). In all cases, Control eyes exhibited the greatest pRNFL thickness, followed by MSnoON eyes, and then MS+ON eyes. pRNFL thinning was not uniform across all peripapillary sectors. In MSnoON eyes, the temporo-superior and infero-nasal sectors appeared more resistant to fiber loss, whereas in MS+ON eyes, all sectors demonstrated significant thinning. Conclusions: Significant pRNFL thinning occurs over time in both MS and healthy eyes. Eyes from MS patients, regardless of a history of optic neuritis, exhibited greater loss than healthy controls. Sectoral analysis suggests differential vulnerability among peripapillary regions. The relative differences between Control, MSnoON, and MS+ON eyes were maintained over a 15-year period.
- 4 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 6072
Open AccessFifteen-Year Longitudinal Changes in Peripapillary Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Background/Objectives: To evaluate changes in peripapillary retinal nerve fiber layer (pRNFL) thickness in patients with multiple sclerosis (MS) and healthy controls over a 15-year period. Methods: This is a retrospective, observational, longitudinal, case-control study. The study included 53 patients with relapsing-remitting MS and 44 age-matched healthy controls. pRNFL thickness was measured using optical coherence tomography (OCT) at baseline (2010) and 15 years later (2025) across 12 peripapillary sectors. Eyes were categorized into three groups: healthy control eyes (Control), eyes from MS patients without a history of optic neuritis (MSnoON), and eyes from MS patients with a history of optic neuritis (MS+ON). Median and interquartile range (IQR) were used for descriptive statistics. Non-parametric tests were applied for statistical analysis. Results: At baseline, the median pRNFL thickness was 94.8 µm in Control eyes, 86.3 µm in MSnoON eyes, and 69.5 µm in MS+ON eyes. After 15 years, the values were 88.5 µm, 80.8 µm, and 59.5 µm, respectively. Intragroup comparisons between 2010 and 2025 showed statistically significant reductions in pRNFL thickness across all three groups (Wilcoxon test, p < 0.05). Intergroup comparisons revealed significant differences among the three groups at both time points (Mann–Whitney test, p < 0.05). In all cases, Control eyes exhibited the greatest pRNFL thickness, followed by MSnoON eyes, and then MS+ON eyes. pRNFL thinning was not uniform across all peripapillary sectors. In MSnoON eyes, the temporo-superior and infero-nasal sectors appeared more resistant to fiber loss, whereas in MS+ON eyes, all sectors demonstrated significant thinning. Conclusions: Significant pRNFL thinning occurs over time in both MS and healthy eyes. Eyes from MS patients, regardless of a history of optic neuritis, exhibited greater loss than healthy controls. Sectoral analysis suggests differential vulnerability among peripapillary regions. The relative differences between Control, MSnoON, and MS+ON eyes were maintained over a 15-year period.
- 27 November 2024
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
Corneal Stress Distribution Using the Procedure of Goldmann Applanation Tonometry, as Tested on a Human Cornea Model
Objective To assess the effect of corneal thinning and changes in intraocular pressure (IOP) on the distribution of corneal stress induced by Goldmann applanation tonometry (GAT). Methods A 2D model of a human cornea was created using a computer-aided design and finite element analysis software, employing previously reported corneal biomechanical properties. The GAT procedure was simulated, and the magnitude and distribution of stress in the corneal stroma were obtained for several corneal thicknesses, stiffnesses, and IOP. Results A significant increase in stress was found in the outer and inner layers of the central cornea and in the inner layers of the surrounding central region. The maximal stress value was observed in the central outer layers when the stiffness was doubled, as in our theoretical baseline cornea (125.16 kPa). Minimal stress was observed in the central inner layers for a central corneal thickness of 300 µm (28.17 kPa). The thickness and stiffness of the cornea significantly influenced the magnitude of the stress, whereas the stress distribution in the cornea did not show significant changes. The change in IOP did not induce significant changes in either stress magnitude or stress distribution. Conclusions The changes and distribution of corneal stress when a GAT procedure is performed support the idea that variations in corneal thickness and stiffness induce changes in corneal biomechanics that may be relevant for IOP readings. These findings are relevant for assessing IOP in corneas that have undergone surgical procedures or have diseases that alter their layers.
- 27 November 2024
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
Corneal Stress Distribution Using the Procedure of Goldmann Applanation Tonometry, as Tested on a Human Cornea Model
Objective To assess the effect of corneal thinning and changes in intraocular pressure (IOP) on the distribution of corneal stress induced by Goldmann applanation tonometry (GAT). Methods A 2D model of a human cornea was created using a computer-aided design and finite element analysis software, employing previously reported corneal biomechanical properties. The GAT procedure was simulated, and the magnitude and distribution of stress in the corneal stroma were obtained for several corneal thicknesses, stiffnesses, and IOP. Results A significant increase in stress was found in the outer and inner layers of the central cornea and in the inner layers of the surrounding central region. The maximal stress value was observed in the central outer layers when the stiffness was doubled, as in our theoretical baseline cornea (125.16 kPa). Minimal stress was observed in the central inner layers for a central corneal thickness of 300 µm (28.17 kPa). The thickness and stiffness of the cornea significantly influenced the magnitude of the stress, whereas the stress distribution in the cornea did not show significant changes. The change in IOP did not induce significant changes in either stress magnitude or stress distribution. Conclusions The changes and distribution of corneal stress when a GAT procedure is performed support the idea that variations in corneal thickness and stiffness induce changes in corneal biomechanics that may be relevant for IOP readings. These findings are relevant for assessing IOP in corneas that have undergone surgical procedures or have diseases that alter their layers.
- Open Access
- 9 July 2024
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 162 (1) , 50-51
Ingestion of an unusually high number of foreign bodies in a mentally ill man
- 9 July 2024
- Published by Elsevier in Journal of Visceral Surgery
- Vol. 162 (1) , 50-51
Open AccessIngestion of an unusually high number of foreign bodies in a mentally ill man
- Open Access
- 3 April 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (6) , e737-e741
Circular statistics for analyzing changes in retinal nerve fiber layer
- 3 April 2024
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (6) , e737-e741
Open AccessCircular statistics for analyzing changes in retinal nerve fiber layer
- 1 February 2023
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 53 (1) , 8-12
Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in this study, eight with unilateral glaucoma and one with bilateral open-angle glaucoma. All of them had been treated with topical PGA for at least one year, before the treatment was discontinued for cosmetic reasons. In all cases, there were evident periocular differences between the treated eye and the fellow eye, consisting mainly of deepening of the upper eyelid sulcus and eyelid fat pad reduction. One year after discontinuing the PGA eye drops, improvement of these features was observed. Clinicians and patients should be aware of the side effects of topical PGA therapy on periorbital tissues, and that these side effects can partially regress after discontinuation of the medication.
- 1 February 2023
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 53 (1) , 8-12
Improvement of Prostaglandin-Associated Periorbitopathy after Discontinuing Treatment
To report that the periorbital changes induced by prostaglandin analogue (PGA) eye drops are partially reversible after discontinuing treatment. Nine patients with prostaglandin-associated periorbitopathy seen in a referral oculoplastic practice were included in this study, eight with unilateral glaucoma and one with bilateral open-angle glaucoma. All of them had been treated with topical PGA for at least one year, before the treatment was discontinued for cosmetic reasons. In all cases, there were evident periocular differences between the treated eye and the fellow eye, consisting mainly of deepening of the upper eyelid sulcus and eyelid fat pad reduction. One year after discontinuing the PGA eye drops, improvement of these features was observed. Clinicians and patients should be aware of the side effects of topical PGA therapy on periorbital tissues, and that these side effects can partially regress after discontinuation of the medication.
- 4 October 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (12) , 1483-1492
Activity and Expression of Carboxylesterases and Arylacetamide Deacetylase in Human Ocular Tissues
As a multi-tissue organ, the eye possesses unique anatomy and physiology including differential expression of drug-metabolizing enzymes. Several hydrolytic enzymes, that play a major role in drug metabolism and bioactivation of prodrugs, have been detected in ocular tissues but data on their quantitative expression is scarce. Also, many ophthalmic drugs are prone to hydrolysis. Metabolic characterization of individual ocular tissues is useful for the drug development process, and therefore, seven individual ocular tissues from human eyes were analyzed for the activity and expression of carboxylesterases (CESs) and arylacetamide deacetylase (AADAC). Generic and selective human esterase substrates 4-nitrophenyl acetate (most esterases), D-luciferin methyl ester (CES1), fluorescein diacetate and procaine (CES2), and phenacetin (AADAC) were applied to determine the enzymes9 specific activities. Enzyme kinetics and inhibition studies were performed with isoform-selective inhibitors digitonin (CES1) and verapamil and diltiazem (CES2). Enzyme contents were determined using quantitative targeted proteomics, and CES2 expression was confirmed by Western blotting. The expression and activity of human CES1 among ocular tissues varied by >10-fold, with the highest levels found in the retina and iris-ciliary body. In contrast, human CES2 expression appeared lower and more similar between tissues whereas AADAC could not be detected. Inhibition studies showed that hydrolysis of fluorescein diacetate is also catalyzed by enzymes other than CES2. This study provides, for the first time, quantitative information on the tissue-dependent expression of human ocular esterases which can be useful for the development of ocular drugs, prodrugs, and in pharmacokinetic modeling of the eye. Significance Statement Novel and comprehensive data on the protein expression and activities of carboxylesterases from individual human eye tissues are generated. In combination with previous reports on pre-clinical species, this study will improve understanding of interspecies differences in ocular drug metabolism and aid the development of ocular pharmacokinetics models.
- 4 October 2022
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 50 (12) , 1483-1492
Activity and Expression of Carboxylesterases and Arylacetamide Deacetylase in Human Ocular Tissues
As a multi-tissue organ, the eye possesses unique anatomy and physiology including differential expression of drug-metabolizing enzymes. Several hydrolytic enzymes, that play a major role in drug metabolism and bioactivation of prodrugs, have been detected in ocular tissues but data on their quantitative expression is scarce. Also, many ophthalmic drugs are prone to hydrolysis. Metabolic characterization of individual ocular tissues is useful for the drug development process, and therefore, seven individual ocular tissues from human eyes were analyzed for the activity and expression of carboxylesterases (CESs) and arylacetamide deacetylase (AADAC). Generic and selective human esterase substrates 4-nitrophenyl acetate (most esterases), D-luciferin methyl ester (CES1), fluorescein diacetate and procaine (CES2), and phenacetin (AADAC) were applied to determine the enzymes9 specific activities. Enzyme kinetics and inhibition studies were performed with isoform-selective inhibitors digitonin (CES1) and verapamil and diltiazem (CES2). Enzyme contents were determined using quantitative targeted proteomics, and CES2 expression was confirmed by Western blotting. The expression and activity of human CES1 among ocular tissues varied by >10-fold, with the highest levels found in the retina and iris-ciliary body. In contrast, human CES2 expression appeared lower and more similar between tissues whereas AADAC could not be detected. Inhibition studies showed that hydrolysis of fluorescein diacetate is also catalyzed by enzymes other than CES2. This study provides, for the first time, quantitative information on the tissue-dependent expression of human ocular esterases which can be useful for the development of ocular drugs, prodrugs, and in pharmacokinetic modeling of the eye. Significance Statement Novel and comprehensive data on the protein expression and activities of carboxylesterases from individual human eye tissues are generated. In combination with previous reports on pre-clinical species, this study will improve understanding of interspecies differences in ocular drug metabolism and aid the development of ocular pharmacokinetics models.
- Open Access
Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine
We describe a case of Vogt-Koyanagi-Harada (VKH) disease exacerbation after COVID-19 vaccination. A 46-year-old woman presented with a bilateral granulomatous uveitis 2 days after the first dose of COVID-19 mRNA vaccine (Comirnaty, Pfizer-BioNTech), and was diagnosed with a complete Vogt-Koyanagi-Harada (VKH) disease 4 days after receiving the second dose of the vaccine. Three weeks before the first dose, she had been consulted for blurred vision and mild headaches. The case resolved with high dose intravenous corticosteroids, followed by oral prednisone. The close temporal relationship between the COVID-19 vaccine doses and the worsening of VKH symptoms strongly suggests COVID-19 vaccination as the trigger of its exacerbation.
Open AccessVogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine
We describe a case of Vogt-Koyanagi-Harada (VKH) disease exacerbation after COVID-19 vaccination. A 46-year-old woman presented with a bilateral granulomatous uveitis 2 days after the first dose of COVID-19 mRNA vaccine (Comirnaty, Pfizer-BioNTech), and was diagnosed with a complete Vogt-Koyanagi-Harada (VKH) disease 4 days after receiving the second dose of the vaccine. Three weeks before the first dose, she had been consulted for blurred vision and mild headaches. The case resolved with high dose intravenous corticosteroids, followed by oral prednisone. The close temporal relationship between the COVID-19 vaccine doses and the worsening of VKH symptoms strongly suggests COVID-19 vaccination as the trigger of its exacerbation.
- Open Access
- 19 October 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1737
Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model
Background: Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has already demonstrated safety and effectiveness in other ocular pathologies. However, TAC eye drops are not marketed, thus their elaboration must be carried out in Hospital Pharmacy Departments (HPDs). Methods: 32 Sprague-Dawley rats were divided into 4 groups of 8 rats each: (a) untreated healthy rats (Healthy); (b) untreated Endotoxin-Induced Uveitis model-rats (EIU); (c) EIU-rats treated with standard treatment of dexamethasone ophthalmic drops (DXM) and (d) EIU-rats treated with TAC-hydroxypropyl-β-cyclodextrin eye drops previously developed by our group (TAC-HPβCD). The mRNA expression levels of IL-6, IL-8, MIP-1α and TNF-α, quantitative analysis of leucocytes in aqueous humor and histological evaluation were performed. Results: TAC-HPβCD eye drops demonstrated to reduce ocular inflammation, expression of IL-6, TNF-α, MIP-1α and leukocyte infiltration in aqueous humor. Conclusions: TAC-HPβCD eye drops showed beneficial effect in EIU model in rats, positioning as an alternative for uveitis treatment in case of corticosteroids resistance or intolerance.
- 19 October 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1737
Open AccessAnti-Inflammatory Effect of Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model
Background: Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has already demonstrated safety and effectiveness in other ocular pathologies. However, TAC eye drops are not marketed, thus their elaboration must be carried out in Hospital Pharmacy Departments (HPDs). Methods: 32 Sprague-Dawley rats were divided into 4 groups of 8 rats each: (a) untreated healthy rats (Healthy); (b) untreated Endotoxin-Induced Uveitis model-rats (EIU); (c) EIU-rats treated with standard treatment of dexamethasone ophthalmic drops (DXM) and (d) EIU-rats treated with TAC-hydroxypropyl-β-cyclodextrin eye drops previously developed by our group (TAC-HPβCD). The mRNA expression levels of IL-6, IL-8, MIP-1α and TNF-α, quantitative analysis of leucocytes in aqueous humor and histological evaluation were performed. Results: TAC-HPβCD eye drops demonstrated to reduce ocular inflammation, expression of IL-6, TNF-α, MIP-1α and leukocyte infiltration in aqueous humor. Conclusions: TAC-HPβCD eye drops showed beneficial effect in EIU model in rats, positioning as an alternative for uveitis treatment in case of corticosteroids resistance or intolerance.
- Open Access
- 23 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 149
Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop
Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration.
- 23 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 149
Open AccessDevelopment and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop
Uveitis is a vision inflammatory disorder with a high prevalence in developing countries. Currently, marketed treatments remain limited and reformulation is usually performed to obtain a tacrolimus eye drop as a therapeutic alternative in corticosteroid-refractory eye disease. The aim of this work was to develop a mucoadhesive, non-toxic and stable topical ophthalmic formulation that can be safely prepared in hospital pharmacy departments. Four different ophthalmic formulations were prepared based on the tacrolimus/hydroxypropyl-β-cyclodextrin (HPβCD) inclusion complexes’ formation. Phase solubility diagrams, Nuclear Magnetic Resonance (NMR) and molecular modeling studies showed the formation of 1:1 and 1:2 tacrolimus/HPβCD inclusion complexes, being possible to obtain a 0.02% (w/v) tacrolimus concentration by using 40% (w/v) HPβCD aqueous solutions. Formulations also showed good ophthalmic properties in terms of pH, osmolality and safety. Stability studies proved these formulations to be stable for at least 3 months in refrigeration. Ex vivo bioadhesion and in vivo ocular permanence showed good mucoadhesive properties with higher ocular permanence compared to the reference pharmacy compounding used in clinical settings (t1/2 of 86.2 min for the eyedrop elaborated with 40% (w/v) HPβCD and Liquifilm® versus 46.3 min for the reference formulation). Thus, these novel eye drops present high potential as a safe alternative for uveitis treatment, as well as a versatile composition to include new drugs intended for topical ophthalmic administration.